SK4862000A3 - The use of 5-ht3 receptor antagonists - Google Patents

The use of 5-ht3 receptor antagonists Download PDF

Info

Publication number
SK4862000A3
SK4862000A3 SK486-2000A SK4862000A SK4862000A3 SK 4862000 A3 SK4862000 A3 SK 4862000A3 SK 4862000 A SK4862000 A SK 4862000A SK 4862000 A3 SK4862000 A3 SK 4862000A3
Authority
SK
Slovakia
Prior art keywords
alosetron
patients
ibs
pharmaceutically acceptable
women
Prior art date
Application number
SK486-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Allen Wayne Mangel
Allison Ruth Northcutt
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK4862000(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SK4862000A3 publication Critical patent/SK4862000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK486-2000A 1997-10-07 1998-10-05 The use of 5-ht3 receptor antagonists SK4862000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments
PCT/EP1998/006278 WO1999017755A2 (fr) 1997-10-07 1998-10-05 Medicaments

Publications (1)

Publication Number Publication Date
SK4862000A3 true SK4862000A3 (en) 2001-01-18

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
SK486-2000A SK4862000A3 (en) 1997-10-07 1998-10-05 The use of 5-ht3 receptor antagonists

Country Status (36)

Country Link
US (3) US6284770B1 (fr)
EP (1) EP1021174A2 (fr)
JP (1) JP2001518495A (fr)
KR (1) KR20010015707A (fr)
CN (1) CN1281357A (fr)
AP (1) AP2000001785A0 (fr)
AR (1) AR017296A1 (fr)
AU (1) AU750818B2 (fr)
BR (1) BR9812886A (fr)
CA (1) CA2305751A1 (fr)
CO (1) CO5011096A1 (fr)
DZ (1) DZ2618A1 (fr)
EA (1) EA003184B1 (fr)
EE (1) EE200000214A (fr)
GB (1) GB9721139D0 (fr)
GT (1) GT199800157A (fr)
HN (1) HN1998000155A (fr)
HR (1) HRP20000198A2 (fr)
HU (1) HUP0003750A3 (fr)
ID (1) ID23874A (fr)
IL (1) IL135398A0 (fr)
IS (1) IS5425A (fr)
MA (1) MA26549A1 (fr)
NO (1) NO20001776L (fr)
NZ (1) NZ503698A (fr)
PA (1) PA8461101A1 (fr)
PE (1) PE120299A1 (fr)
PL (1) PL340337A1 (fr)
SK (1) SK4862000A3 (fr)
SV (1) SV1998000122A (fr)
TN (1) TNSN98179A1 (fr)
TR (1) TR200000913T2 (fr)
UY (1) UY25200A1 (fr)
WO (1) WO1999017755A2 (fr)
YU (1) YU20600A (fr)
ZA (1) ZA989061B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (fr) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Utilisation de (R)-zacopride ou d'un de ses sels dans la fabrication d'un médicament pour le traitement de l'apnée du sommeil
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
ES2357808T3 (es) * 2001-06-07 2011-04-29 Christine Dr. Sang Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda).
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
CA2473392A1 (fr) 2002-01-18 2003-07-31 Aryx Therapeutics Antagonistes du recepteur 5-ht3 et leurs procedes d'utilisation
WO2004004734A1 (fr) * 2002-07-10 2004-01-15 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine destinee a traiter un trouble intestinal fonctionnel
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
JP4399862B2 (ja) * 2002-08-09 2010-01-20 味の素株式会社 腸疾患および内臓痛の治療薬
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
PL378369A1 (pl) * 2003-01-13 2006-04-03 Dynogen Pharmaceuticals, Inc. Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
CA2550886A1 (fr) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Formes polymorphiques de la base du tegaserod et des sels de celui-ci
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
MXPA05009025A (es) * 2004-01-30 2006-04-27 Astellas Pharma Inc Agentes de tratamiento para el sindrome de intestino delgado irritado con diarrea predominante.
WO2005073220A1 (fr) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remede contre le syndrome du colon irritable avec diarrhee
AU2005213305A1 (en) * 2004-02-03 2005-08-25 Daniel Rachmilewitz Methods of treating irritable bowel syndrome
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1724267B1 (fr) 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Derive de pyrimidine
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
WO2006105117A2 (fr) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Procede destine a traiter des troubles et des conditions au moyen d'inhibiteurs et d'antagonistes a peripherie restreinte
EP1902053B1 (fr) * 2005-06-07 2011-01-12 Theravance, Inc. Composes de benzoimidazolone-carboxamide en tant qu'agonistes du recepteur 5-ht4
WO2007000046A1 (fr) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methodes de diagnostic de maladie intestinale fonctionnelle
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
WO2007097197A1 (fr) * 2006-02-20 2007-08-30 Astellas Pharma Inc. Dérivé d'amine ou sel de celui-ci
WO2009053754A2 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouvelles formes cristallines
WO2009053750A2 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouvelles formes cristallines et amorphes
WO2009053733A2 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouvelles formes cristallines
WO2009053732A1 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouveau sel
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
US8343552B2 (en) 2007-12-28 2013-01-01 Liveleaf, Inc. Therapeutic composition produced using punica granatum and hydrogen peroxide
US8568743B2 (en) 2009-04-29 2013-10-29 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
JP5741433B2 (ja) * 2009-06-30 2015-07-01 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
JP2014530249A (ja) * 2011-10-18 2014-11-17 ヘルシン ヘルスケア ソシエテ アノニム ネツピタントおよびパロノセトロンの治療学的組合せ
JP2015531346A (ja) 2012-09-05 2015-11-02 チェイス・ファーマスーティカルズ・コーポレーション 抗コリン作用性神経保護組成物及び方法
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (fr) 1986-07-25 1992-10-07 Beecham Group Plc Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique
GB8806990D0 (en) * 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) 1987-01-19 1987-02-18 Beecham Group Plc Treatment
GB2209335B (en) * 1987-09-03 1991-05-29 Glaxo Group Ltd Lactam derivatives
DE3850742T2 (de) * 1987-11-04 1994-10-27 Beecham Group Plc Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
EP0336759A1 (fr) * 1988-04-07 1989-10-11 Glaxo Group Limited Dérivés d'imidazole
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
US5017573A (en) * 1988-07-29 1991-05-21 Dainippon Pharmaceutical Co., Ltd. Indazole-3-carboxylic acid derivatives
GB8820650D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) * 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (fr) * 1989-03-14 1990-09-19 Beecham Group Plc Dérivés d'imidazole, procédés de leur préparation et leur application comme produits pharmaceutiques
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
AU1161292A (en) * 1991-01-09 1992-08-17 Smithkline Beecham Plc Azabicydic and azatricydic derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
EA003184B1 (ru) 2003-02-27
HUP0003750A2 (hu) 2001-10-28
TR200000913T2 (tr) 2001-01-22
NO20001776L (no) 2000-06-06
HUP0003750A3 (en) 2003-02-28
GT199800157A (es) 2000-03-30
WO1999017755A2 (fr) 1999-04-15
NZ503698A (en) 2002-10-25
IS5425A (is) 2000-03-31
US20010044450A1 (en) 2001-11-22
YU20600A (sh) 2003-10-31
DZ2618A1 (fr) 2003-03-01
EP1021174A2 (fr) 2000-07-26
AU750818B2 (en) 2002-07-25
JP2001518495A (ja) 2001-10-16
HRP20000198A2 (en) 2001-04-30
SV1998000122A (es) 1999-07-05
AU9629398A (en) 1999-04-27
US6593336B2 (en) 2003-07-15
PA8461101A1 (es) 2000-05-24
PE120299A1 (es) 1999-12-15
GB9721139D0 (en) 1997-12-03
ZA989061B (en) 2001-07-05
NO20001776D0 (no) 2000-04-06
MA26549A1 (fr) 2004-12-20
TNSN98179A1 (fr) 2005-03-15
BR9812886A (pt) 2000-08-08
AP2000001785A0 (en) 2000-06-30
HN1998000155A (es) 1999-05-24
UY25200A1 (es) 2001-01-31
CO5011096A1 (es) 2001-02-28
WO1999017755A3 (fr) 1999-09-23
US20030036549A1 (en) 2003-02-20
ID23874A (id) 2000-05-25
IL135398A0 (en) 2001-05-20
US6284770B1 (en) 2001-09-04
AR017296A1 (es) 2001-09-05
US6429209B2 (en) 2002-08-06
CA2305751A1 (fr) 1999-04-15
KR20010015707A (ko) 2001-02-26
PL340337A1 (en) 2001-01-29
EE200000214A (et) 2001-06-15
CN1281357A (zh) 2001-01-24
EA200000299A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
SK4862000A3 (en) The use of 5-ht3 receptor antagonists
DE60106281T2 (de) Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
DE602004005814T2 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
KR100469029B1 (ko) 세로토닌재흡수억제제의위장효과를극복하기위한5ht4수용체길항제의용도
ITMI941048A1 (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
SK281603B6 (sk) Použitie 5ht3 antagonistu na prípravu farmaceutickej zmesi na liečenie fibromyalgie
EA030145B1 (ru) Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
WO2019139244A1 (fr) Composition pharmaceutique contenant un inhibiteur d'hdac6 en tant que principe actif pour la prévention ou le traitement des démangeaisons
CA2845039A1 (fr) Combinaisons d'un agoniste de recepteur 5-ht4 et d'un inhibiteur de pde4 pour utilisation en therapie
EP1276476A2 (fr) Utilisation d'agents bradycardiques dans le traitement de maladies myocardiaques accompagnees d'hypertrophie et nouvelles combinaisons pharmaceutiques
WO2021023877A2 (fr) Compositions et méthodes de traitement de troubles dépendant des œstrogènes
US5155126A (en) Treatment of central nervous system disorders with pyrazole, pyrrole and triazole angiotensin-II receptor antagonists
SK4542002A3 (en) Synergistic combinations of an NK1 receptor antagonist and a GABA structural analog
CA2362918A1 (fr) Procedes et compositions pour le traitement de la dyserection
EA000531B1 (ru) Активное вещество при производстве фармацевтического препарата для лечения травматического повреждения головного мозга
US4312879A (en) Clonidine and lofexidine as antidiarrheal agents
CZ119197A3 (en) Benzothiophene for preparing a medicament
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung
CZ20001259A3 (cs) Farmaceutický prostředek
RU2761219C2 (ru) Терапевтическое средство от расстройств, связанных с употреблением алкоголя
US4363809A (en) Organic compounds
US4904673A (en) Agent for treating bradycardia and bradyarrhythmia
CZ2001150A3 (cs) Lék pro léčbu psychóz nebo jiných neuropsychiatrických příznaků u pacientů s Alzheimerovou chorobou